De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian, Robert Paul
De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study. [electronic resource] - American journal of hematology Nov 2014 - E193-9 p. digital
Publication Type: Comparative Study; Journal Article; Multicenter Study
1096-8652
10.1002/ajh.23808 doi
Age Factors
Aged
Aged, 80 and over
Anemia, Refractory, with Excess of Blasts--genetics
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bone Marrow--pathology
Cell Count
Chromosome Aberrations
DNA Methylation--drug effects
Female
Hematopoietic Stem Cell Transplantation
Humans
Kaplan-Meier Estimate
Karyotype
Leukemia, Myeloid, Acute--genetics
Male
Middle Aged
Mutation
Neoplasm Proteins--genetics
Neoplastic Stem Cells--pathology
Nuclear Proteins--genetics
Nucleophosmin
Prognosis
Remission Induction
Retrospective Studies
Treatment Outcome
fms-Like Tyrosine Kinase 3--genetics
De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study. [electronic resource] - American journal of hematology Nov 2014 - E193-9 p. digital
Publication Type: Comparative Study; Journal Article; Multicenter Study
1096-8652
10.1002/ajh.23808 doi
Age Factors
Aged
Aged, 80 and over
Anemia, Refractory, with Excess of Blasts--genetics
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bone Marrow--pathology
Cell Count
Chromosome Aberrations
DNA Methylation--drug effects
Female
Hematopoietic Stem Cell Transplantation
Humans
Kaplan-Meier Estimate
Karyotype
Leukemia, Myeloid, Acute--genetics
Male
Middle Aged
Mutation
Neoplasm Proteins--genetics
Neoplastic Stem Cells--pathology
Nuclear Proteins--genetics
Nucleophosmin
Prognosis
Remission Induction
Retrospective Studies
Treatment Outcome
fms-Like Tyrosine Kinase 3--genetics